FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2938959916> ?p ?o ?g. }

• W2938959916 endingPage "552" @default.
• W2938959916 startingPage "537" @default.
• W2938959916 abstract "BackgroundAcromegaly is produced by excess growth hormone secreted by a pituitary adenoma of somatotroph cells (ACRO). First-line therapy, surgery and adjuvant therapy with somatostatin analogs, fails in 25% of patients. There is no predictive factor of resistance to therapy. New therapies are investigated using few dispersed tumor cells in acute primary cultures in standard conditions where the cells do not grow, or using rat pituitary cell lines that do not maintain the full somatotroph phenotype. The RET/PIT1/p14ARF/p53 pathway regulates apoptosis in normal pituitary somatotrophs whereas the RET/GDNF pathway regulates survival, controlling PIT1 levels and blocking p14ARF (ARF) and p53 expression.MethodsWe investigated these two RET pathways in a prospective series of 32 ACRO and 63 non-functioning pituitary adenomas (NFPA), studying quantitative RNA and protein gene expression for molecular-clinical correlations and how the RET pathway might be implicated in therapeutic success. Clinical data was collected during post-surgical follow-up. We also established new'humanized’ pituitary cultures, allowing 20 repeated passages and maintaining the pituitary secretory phenotype, and tested five multikinase inhibitors (TKI: Vandetanib, Lenvatinib, Sunitinib, Cabozantinib and Sorafenib) potentially able to act on the GDNF-induced RET dimerization/survival pathway. Antibody arrays investigated intracellular molecular pathways.FindingsIn ACRO, there was specific enrichment of all genes in both RET pathways, especially GDNF. ARF and GFRA4 gene expression were found to be opposing predictors of response to first-line therapy. ARF cut-off levels, calculated categorizing by GNAS mutation, were predictive of good response (above) or resistance (below) to therapy months later. Sorafenib, through AMPK, blocked the GDNF/AKT survival action without altering the RET apoptotic pathway.InterpretationTumor ARF mRNA expression measured at the time of the surgery is a prognosis factor in acromegaly. The RET inhibitor, Sorafenib, is proposed as a potential treatment for resistant ACRO.FundThis project was supported by national grants from Agencia Estatal de Investigación (AEI) and Instituto Investigación Carlos III, with participation of European FEDER funds, to IB (PI150056) and CVA (BFU2016-76973-R). It was also supported initially by a grant from the Investigator Initiated Research (IIR) Program (WI177773) and by a non-restricted Research Grant from Pfizer Foundation to IB. Some of the pituitary acromegaly samples were collected in the framework of the Spanish National Registry of Acromegaly (REMAH), partially supported by an unrestricted grant from Novartis to the Spanish Endocrine Association (SEEN).CVA is also supported from a grant of Medical Research Council UK MR/M018539/1." @default.
• W2938959916 created "2019-04-25" @default.
• W2938959916 creator A5001697468 @default.
• W2938959916 creator A5004536495 @default.
• W2938959916 creator A5014359070 @default.
• W2938959916 creator A5025762720 @default.
• W2938959916 creator A5035962265 @default.
• W2938959916 creator A5040170615 @default.
• W2938959916 creator A5044905998 @default.
• W2938959916 creator A5052718146 @default.
• W2938959916 creator A5053569138 @default.
• W2938959916 creator A5056991320 @default.
• W2938959916 creator A5065181657 @default.
• W2938959916 creator A5067149370 @default.
• W2938959916 creator A5069060002 @default.
• W2938959916 creator A5083759182 @default.
• W2938959916 creator A5090007694 @default.
• W2938959916 creator A5091689615 @default.
• W2938959916 date "2019-05-01" @default.
• W2938959916 modified "2023-10-14" @default.
• W2938959916 title "Unmasking a new prognostic marker and therapeutic target from the GDNF-RET/PIT1/p14ARF/p53 pathway in acromegaly" @default.
• W2938959916 cites W1575789471 @default.
• W2938959916 cites W1826835337 @default.
• W2938959916 cites W1889842940 @default.
• W2938959916 cites W1964034933 @default.
• W2938959916 cites W1966720250 @default.
• W2938959916 cites W1968686660 @default.
• W2938959916 cites W1974824979 @default.
• W2938959916 cites W1975096978 @default.
• W2938959916 cites W1976654629 @default.
• W2938959916 cites W1981810931 @default.
• W2938959916 cites W1982060052 @default.
• W2938959916 cites W1984776559 @default.
• W2938959916 cites W1988787595 @default.
• W2938959916 cites W1992786709 @default.
• W2938959916 cites W1995478805 @default.
• W2938959916 cites W2013824261 @default.
• W2938959916 cites W2014078232 @default.
• W2938959916 cites W2023285758 @default.
• W2938959916 cites W2023443384 @default.
• W2938959916 cites W2028093783 @default.
• W2938959916 cites W2034316534 @default.
• W2938959916 cites W2035630269 @default.
• W2938959916 cites W2041752091 @default.
• W2938959916 cites W2045359362 @default.
• W2938959916 cites W2050264451 @default.
• W2938959916 cites W2054935117 @default.
• W2938959916 cites W2066019345 @default.
• W2938959916 cites W2068219524 @default.
• W2938959916 cites W2069900263 @default.
• W2938959916 cites W2084891010 @default.
• W2938959916 cites W2096735709 @default.
• W2938959916 cites W2096910745 @default.
• W2938959916 cites W2098511103 @default.
• W2938959916 cites W2103199528 @default.
• W2938959916 cites W2106332666 @default.
• W2938959916 cites W2107482780 @default.
• W2938959916 cites W2119666459 @default.
• W2938959916 cites W2121536412 @default.
• W2938959916 cites W2128443399 @default.
• W2938959916 cites W2135676923 @default.
• W2938959916 cites W2138736796 @default.
• W2938959916 cites W2147499685 @default.
• W2938959916 cites W2151821298 @default.
• W2938959916 cites W2153406820 @default.
• W2938959916 cites W2155465275 @default.
• W2938959916 cites W2158287682 @default.
• W2938959916 cites W2158629056 @default.
• W2938959916 cites W2160980881 @default.
• W2938959916 cites W2166330620 @default.
• W2938959916 cites W2190745596 @default.
• W2938959916 cites W2208793511 @default.
• W2938959916 cites W2267051237 @default.
• W2938959916 cites W2274145807 @default.
• W2938959916 cites W2339053009 @default.
• W2938959916 cites W2398850749 @default.
• W2938959916 cites W2412783057 @default.
• W2938959916 cites W2419009425 @default.
• W2938959916 cites W2489385611 @default.
• W2938959916 cites W2528324838 @default.
• W2938959916 cites W2590629289 @default.
• W2938959916 cites W2613309744 @default.
• W2938959916 cites W2621969338 @default.
• W2938959916 cites W2625024000 @default.
• W2938959916 cites W2735903588 @default.
• W2938959916 cites W2737796269 @default.
• W2938959916 cites W2749487675 @default.
• W2938959916 cites W2776104508 @default.
• W2938959916 cites W2783104796 @default.
• W2938959916 cites W2803170943 @default.
• W2938959916 cites W2884285576 @default.
• W2938959916 cites W2888759088 @default.
• W2938959916 cites W2889103264 @default.
• W2938959916 doi "https://doi.org/10.1016/j.ebiom.2019.04.007" @default.
• W2938959916 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/6562173" @default.
• W2938959916 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/30975543" @default.
• W2938959916 hasPublicationYear "2019" @default.
• W2938959916 type Work @default.

• next